We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Calls for More Data in Pfizer’s Herceptin Biosimilar Application
FDA Calls for More Data in Pfizer’s Herceptin Biosimilar Application
The FDA sent Pfizer a complete response letter for its proposed biosimilar of Genentech’s Herceptin (trastuzumab), saying it needs to see more data before approving the breast cancer drug.